TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06561321
Drug: Tapinarof
Normalized name: Tapinarof
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily topical Tapinarof use will stop disease advancement and improve the quality of life in patients with palmoplantar keratoderma, through its AhR \& NRF2 agonism properties.
Study: NCT05526755
Drug: Osimertinib 80 mg/40 mg
Normalized name: osimertinib 80 MG
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
Study: NCT06470048
Drug: Ianalumab
Normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous (s.c.) injection as defined in the protocol
Study: NCT05303532
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
Study: NCT05306431
Drug: Polyhexamethylene biguanide
Normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
Study: NCT05306431
Drug: Sodium Hypochlorite
Normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
Study: NCT06347497
Drug: Zonisamide 50 MG
Normalized name: zonisamide 50 MG
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05299073
Drug: MB09
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of 35mg SC administered
Study: NCT05299073
Drug: US-sourced Xgeva
Normalized name: Xgeva
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of 35mg SC administered
Study: NCT05299073
Drug: EU-sourced Xgeva
Normalized name: Xgeva
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of 35mg SC administered
Study: NCT06347497
Drug: Topiramate 50 MG
Normalized name: topiramate 50 MG
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05772208
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab 200mg q3w
Study: NCT05772208
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimotuzumab 200mg qw
Study: NCT05772208
Drug: neoadjuvant chemotherapy and CCRT
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
Study: NCT06227338
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg).
Study: NCT05007821
Drug: Linezolid 600 mg
Normalized name: linezolid 600 MG
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
Study: NCT05007821
Drug: Linezolid 1200 mg (QD)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
Study: NCT05007821
Drug: Linezolid 1200 mg (TIW)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
Study: NCT05007821
Drug: Bedaquiline 200 mg
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two 100mg tablets taken orally once daily in the morning during weeks 1-8
Study: NCT05007821
Drug: Bedaquiline 100 mg
Normalized name: bedaquiline 100 MG
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 100mg tablet taken orally once daily in the morning during weeks 9-26
Study: NCT05007821
Drug: Delamanid 300 mg
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Six 50mg tablets taken orally once daily in the morning during weeks 1-26
Study: NCT05007821
Drug: Clofazimine 300 mg
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three 100mg capsules taken orally once daily in the morning during weeks 1-2
Study: NCT05007821
Drug: Clofazimine 100 mg
Normalized name: clofazimine 100 MG
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 100mg capsule taken orally once daily in the morning during weeks 3-26
Study: NCT04837716
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04837716
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04837716
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT06123286
Drug: Tart Cherry
Normalized name: Tart Cherry
DrugBank: Cherry (DB10518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
Study: NCT05204563
Drug: Combination of Imipenem/Cilastatin and XNW4107
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
Study: NCT05204563
Drug: Imipenem/Cilastatin/Relebactam
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Imipenem/Cilastatin/Relebactam 1.25 g for Injection
Study: NCT05568407
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As used in real world practice
Study: NCT05574998
Drug: Recombinant human endostatin (Endostar)
Normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed.
Study: NCT05720533
Drug: Disitamab Vedotin Combined With Sintilimab
Normalized name: Brentuximab Vedotin
DrugBank: Sintilimab (DB15765)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
Study: NCT05607550
Drug: platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Study: NCT05683223
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
Study: NCT05619367
Drug: Odronextamab
Normalized name: Odronextamab
DrugBank: Odronextamab (DB16684)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05722015
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
Study: NCT05722015
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
Study: NCT05722015
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
Study: NCT05722015
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Study: NCT05722015
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
Study: NCT05722015
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim will be administered as per the schedule specified for the arm.
Study: NCT05722015
Drug: Pegylated filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pegylated filgrastim will be administered as per the schedule specified for the arm.
Study: NCT00293839
Drug: oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06277791
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab：20mg/kg, ivdrip, D1，Q3W
Study: NCT06153420
Drug: CIN-103
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIN-103 BID
Study: NCT05456490
Drug: Liposomal Bupivacaine 13.3
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the Intrathecal space
Study: NCT05456490
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the Intrathecal space
Study: NCT06456346
Drug: Bomedemstat
Normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06456346
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06456346
Drug: Bomedemstat placebo
DrugBank: Bomedemstat (DB17234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule placebo
Study: NCT05798520
Drug: DRF
Normalized name: EDRF
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04411654
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV pulse administered as concomitant medication.
Study: NCT04411654
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
Study: NCT04411654
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally as concomitant medication, followed by dose tapering.
Study: NCT04753697
Drug: CC-93538
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous
Study: NCT06031415
Drug: GS-0272
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
Study: NCT06343090
Drug: CD19 CAR T-cell
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murine-derived CD19 CAR T cells
Study: NCT06343090
Drug: CD22 CAR T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized CD22 CAR T cells
Study: NCT05575011
Drug: BIIB115
Normalized name: BIIB115
DrugBank: BIIB115 (DB18418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05575011
Drug: BIIB115-Matching Placebo
DrugBank: BIIB115 (DB18418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT04736823
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04736823
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT04736823
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04736823
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT04736823
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05465031
Drug: Sacubitril-valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
Study: NCT06200467
Drug: BI 456906
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT06200467
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT06200467
Drug: Placebo to moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT06640413
Drug: L19IL2
Normalized name: L19IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 Mio IU
Study: NCT06266338
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV q 3 weeks
Study: NCT06266338
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg PO daily
Study: NCT05686070
Drug: Asundexian (BAY2433334)
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT06324435
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60mg/day
Study: NCT06142383
Drug: Sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT06374095
Drug: RATG
Normalized name: rATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin, Genzyme corporation, Italy.
Study: NCT06374095
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simulect, Novartis, Italy.
Study: NCT05653713
Drug: CSL324
Normalized name: CSL324
DrugBank: CSL324 (DB16359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) dose of CSL324
Study: NCT05673187
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
Study: NCT06639087
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive dapagliflozin once daily with AZD5462 or placebo.
Study: NCT05966792
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
Study: NCT05966792
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Study: NCT05885542
Drug: Cannabidiol oral solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Double-blind cannabidiol oral solution 800 mg administered once
Study: NCT05501574
Drug: Tacrolimus Inhalation Powder
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus powder for inhalation to prevent acute allograft rejection
Study: NCT05514132
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
Study: NCT05514132
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
Study: NCT04881240
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
Study: NCT04881240
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
Study: NCT05476926
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab will be administered as per local clinical practice and local labeling.
Study: NCT04891588
Drug: Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months
Study: NCT00000695
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no